stockportfolio.pro
Stocks / RLAY vs TLX
RLAY vs TLX
Relay Therapeutics, Inc. and Telix Pharmaceuticals Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Relay Therapeutics, Inc. (RLAY) | Telix Pharmaceuticals Limited (TLX) | |
|---|---|---|
| Market cap | $3.1B | $3.2B |
| Revenue (latest FY) | $15.36M | $803.79M |
| Net income (latest FY) | $-276.48M | $-7.13M |
| Revenue growth (5y CAGR) | -28.6% | 94.7% |
| Net margin | -1800.6% | -0.9% |
| Return on equity | -48.8% | -1.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RLAY — free Open TLX — freeFrequently asked questions
Which is bigger, RLAY or TLX?
Telix Pharmaceuticals Limited is larger by market capitalization — $3.2B versus $3.1B.
Which grows faster, RLAY or TLX?
Over the last five fiscal years, Telix Pharmaceuticals Limited grew revenue faster — 94.7%/yr versus -28.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.